Introduction
Nearly all viruses give rise to defective interfering (DI) virus variants. These arise spontaneously and are characterized by deletions in their genome so that they are replicated only in cells co-inoculated with the infectious virus from which they arose. When there are low ratios of DI:infectious virus in the infected cell, DI virus genomes are amplified relative to those of infectious virus, but at high ratios of DI:infectious virus there is interference with the multiplication of infectious virus. These properties of the DI virus are usually restricted to the infectious virus from which it originated (Huang & Baltimore, 1970) . Although by definition all DI viruses have the property of interference in cell culture, there are relatively few examples of the modulation of infection in animals by DI viruses. The best studied are DI vesicular stomatitis virus, Semliki Forest virus and type A influenza virus (reviewed by Barrett & Dimmock, 1986; Dimmock, 199l; Roux et al., 1991) . In this report we have investigated DI equine influenza virus (DI EQV: H3NS). Not only is this a different subtype from that studied previously [the human strain WSN (HIN1): Dimmock et Morgan et al., 1993) , but EQV is a natural pathogen of horses. DI EQV protected mice against both infectious homologous and heterologous subtypes and, in contrast to DI WSN, acted by inhibiting virus multiplication.
Methods
Cells. MDCK cells were obtained from Flow Laboratories and were cultured in Dulbecco's modified Eagle's medium supplemented with 5 % newborn calf serum, 0-02 mM-glutamine, 100 units/ml penicillin and 100 tag/ml streptomycin.
Viruses. A strain of influenza virus A/equine/Newmarket/A/7339/79 (EQV: H3N8) capable of causing experimental influenza in ponies was obtained from Dr J. A. Mumford. Stocks of EQV, A/WSN (H1N1) and A/PR/8/34 (HIN1) (103 p.f.u, inoculated per egg) were grown in the allantoic activity of embryonated chicken's eggs. Infectivity was measured by plaque assay in MDCK cells. The total amount of virus present was assayed by haemagglutination (HA) of chick red blood cells. Defective interfering (DI) EQV was prepared by three serial high multiplicity passages in eggs of standard (non-mouse adapted) virus. The second passage was stored as a seed stock and given a single passage as required to make DI virus inocula for mice. Third passage DI virus was partially purified and concentrated by differential centrifugation to 104 HAU (haemagglutinating units)/ml. . This has a p.f.u. :HU ratio of about 103. DI virus was UV irradiated for about 20 s to remove residual infectivity and, as shown before, this had little effect on interfering activity due to the relatively small size of the DI genome (Dimmock & Kennedy, 1978) . Interfering activity was inactivated by prolonged u.v. irradiation for 4 min. HA and neuraminidase activities were not affected, and this virus was used as an antigen control.
Mice. C3H/He-mg (H-2 ~) mice were originally obtained from Bantin & Kingman Ltd (Grimston, Aldborough, Hull, U.K.) and subsequently bred at Warwick University Animal Facility. All experiments followed the guidelines laid down by the U.K. Coordinating Committee for Cancer Research. EQV was adapted to lethal infection of mice by serial mous~egg mouse passage of lung homogenate. For lethal infections, we used approximately 10 LDs0 of EQV containing 2 x 104 p.f.u., 10 LDs0 of WSN containing 2.3 x 103 p.f.u, and 10 LDs0 of PR8 containing 1.6 x 102 p.f.u. For morbidity experiments we used 180 p.f.u. WSN/mouse. Five-week-old mice, of either sex, were inoculated intranasally under light ether anaesthesia with two intranasal doses (20 btl), given 2 h apart, of non-infectious DI virus or inactivated (i.e. non-interfering) DI virus. DI preparations usually contained 400 HAU. Departures from this are indicated in the text. The second dose contained the required amount of infectious virus . When required mice were killed with CO s . Lungs were removed at intervals and the percentage of consolidation estimated by eye. For infectivity titrations, lungs were ground with sand in a pestle and mortar, resuspended in 3 ml PBS containing 0-1% w/v BSA and clarified by low-speed centrifugation before being stored at -70 °C. In most experiments, we assessed morbidity as a measure of infection: such mice showed signs of malaise, inactivity, ruffled fur especial[y around the head and neck, respiratory distress and failure to gain weight. This was almost always accompanied by an altered gait, a hunched posture and laterally constricted abdomen, and sometimes by r/des. In addition, morbidity was estimated by failure to gain weight. Mice were weighed daily and the weight expressed as a percentage of that on the day after infection. during infection with WSN Morgan et al., 1993) . However, mice inoculated with 10 LD~0 EQV+active DI EQV showed no clinical signs and were indistinguishable from non-infected, agematched controls. All mice inoculated intranasally with |0 LD~0 EQV+inactivated DI EQV developed signs of morbidity and 25 % died. Thus the inactivated DI virus preparation afforded some protection compared to infection with WSN alone.
Results

DI EQ V protects mice against morbidity and mortality caused by EQ V
Protection by inactivated DI EQV may have been due to residual interference or to the stimulation of protective immunity. The latter was examined by inoculating mice intranasally as described with either two doses of PBS, active DI EQV or inactivated DI EQV, but without infectious EQV. After 24 days, mice were challenged with EQV. There was marginal protection of 25 % (2/8) of mice originally inoculated with active or inactivated DI EQV which failed to develop clinical signs of disease, compared with none of the mock-inoculated mice (data not shown), suggesting that both DI virus preparations stimulated a low level immunity in a small proportion of mice. However, since active DI EQV was no more protective than inactivated DI EQV, we conclude that the greater protection exerted by active DI EQV compared with inactivated DI EQV in Fig. 1 resulted from the interfering properties of its genome and not from its immunogenic potential.
D1 EQV protects mice against lethal infection with WSN and PR8
DI viruses usually interfere only with the strain of virus from which they were derived, but at least in vitro DI influenza A viruses are an exception (De & Nayak, 1980 ).
Here we have tested cross-protection in vivo. Table 1 shows that DI EQV (H3N8) completely protected mice, inoculated as described above, from either of the human type A (H1N1) influenza viruses, WSN or PR8. There was no mortality; only very occasionally did mice show any sign of morbidity and this was always of a mild nature. In comparison there was about 80 % mortality of WSN-infected mice and 60 to 70 % mortality of PR8-infected mice which were treated with inactivated DI EQV or were mock-treated with PBS. Inactivated DI EQV gave no protection against WSN or PR8 unlike the situation with EQV in Fig. 1 . Fig. 2 shows that the infectivity in extracts of lungs taken at 3, 5 and 7 days after infection with about 10 LDs0 WSN was reduced between 20-and 60-fold as a result of co-inoculation with DI WSN compared with mice co- (40) * Five-week-old mice were treated with an intranasal dose of the material indicated, and then 2 h later were given a second dose of the same material containing 10 LDs0 of WSN or 10 LDs0 of PR8.
DI EQ V inhibits the multiplication in the lung of a lethal dose of WSN
t Number of mice surviving at 12 days after infection/number of mice inoculated. inoculated with inactivated DI EQV. This suggested that DI EQV protected mice by inhibiting virus multiplication in the lung. No infectivity was recovered from the lung in samples taken at 9, 11, 13 and 15 days after infection even when unclarified lung suspension was inoculated into embryonated chicken's eggs for 3 days at 33 °C to enhance recovery (data not shown). Thus infectious virus was cleared rapidly from mice receiving WSN + DI EQV and there was no evidence of persistence as has been seen with some DI virus systems (Dimmock, 1991; Roux et al., 1991) .
Quantification of the protective dose of DI EQ V
Mice were inoculated with serial dilutions of DI EQV in the usual way together with about 10 LD~0 WSN. Whereas the standard dose of DI EQV (400 HAU) completely protected mice from any sign of clinical * Five-week-old mice (six to eight mice/group) were treated with a single intranasal dose of the material indicated (measured in HAU), and then 2 h later were given a second dose of the same material containing 10 LDs0 WSN.
~ Five-week-old mice were given a single dose ofDI EQV containing 10 LDs0 WSN. * Five-week-old mice were treated with two intranasal doses of the material indicated and then infected on the day shown with 10 LDs0 WSN by the same route. Mice inoculated on day 0 were given one dose of DI EQV or inactivated DI EQV followed 2 h later by co-inoculation of the same material containing WSN. Each group comprised 15 or 16 mice.
disease, a 10-fold dilution halved the protection, and a 100-fold dilution abrogated protection altogether. A single dose of DI EQV protected nearly as well as the normal double dose (Table 2) .
Prophylactic treatment of mice with DI EQ V protects against infection with a lethal dose of WSN
Mice were given two doses of DI EQV or inactivated DI EQV intranasally with a 2 h interval, and then infected with WSN at various daily intervals up to 7 days later. Table 3 shows that protection was undiminished at 3 days after inoculation of DI virus. Inactivated DI EQV afforded a degree of protection, as seen above in Fig. 1 , but the protection mediated by active DI EQ¥ was significantly greater at 5 days after its inoculation. No protection could be ascribed specifically to DI EQV at 7 days after its inoculation although there was some sparing effect, again presumably immunologically based. Treatment of mice at 1 day after infection was ineffective. 
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Determination of the dose of DI EQ V needed to afford protection against a 'low' dose of WSN that causes mainly morbidity
The experiments described above used a lethal dose of EQV or WSN. However, influenza is rarely fatal in horses or man, so in order to devise a better model, we titrated WSN to find a dose which caused morbidity with only a low level of mortality (data not shown). In Fig.  3 (a to c) Protection of mice by DI equine influenza virus 3489 completely protected from overt disease by a 100-fold dilution of DI EQV (equivalent to 4 HAU/mouse), whereas mice given the same dilution of inactivated DI EQV suffered 70% morbidity. There was significant (38 %) protection even with 0.4 HAU (1.2 ng) DI EQV per mouse (Fig. 3 d) .
In addition to the overall clinical assessment of morbidity, the weight gain of mice during the course of the experiments was also monitored. Fig. 4(c) shows that there was a steady weight gain in control (non-infected) mice for the duration of the experiment, whereas infected mice showed no gain or even lost weight. Mice inoculated with WSN +inactivated DI EQV gained no weight for about 7 days after infection, and then gained weight at the same rate as non-infected mice (Fig. 4d) . However, even after 19 days, they were still underweight. Weight gain in infected mice which had been protected with active DI WSN was indistinguishable from that of noninfected animals (Fig. 4a, b, d ). Thus the objective parameter of weight gain supported the clinical assessment in Fig. 3 .
Discussion
DI EQV protected adult mice against the morbidity and mortality caused by intranasatly inoculated EQV (H3N8), as well as against the morbidity and mortality caused by strains of a different subtype (H1NI: WSN and PR8). Protection was substantially reduced after DI EQV had been subjected to prolonged u.v. irradiation suggesting that the DI genome was largely responsible. However, inactivated DI EQV afforded a lesser and variable degree of protection against EQV (Fig. 1) and WSN (Table 3) suggesting that it had residual DI protecting activity remaining or that it was slightly immununogenic.
DI EQV (H3N8) protected as well heterotypically against WSN and PR8 (both H1N1) as it did homotypically, although in general DI viruses interact only with the virus strain from which they arose. Occasional exceptions have been reported for strains of vesicular stomatitis virus (Prevec & Kang, 1970; Schnitzlein & Reichman, 1976) , Semliki Forest virus (Barrett & Dimmock, 1984b) and West Nile virus (Debnath et al., 1991) . Homotypic interference probably reflects a requirement for the recognition of control (replication and encapsidation) sequences in the DI genome by replication and virion proteins expressed by infectious virus enzymes (Giachetti & Holland, 1988) . However, type A influenza viruses may be the exception as others have found substantial cross-interference in vitro between DI viruses of H1N1, H2N2 and H3N2 subtypes (De & Nayak, 1980) and more limited interference in vitro between DI H1NI virus and a H7N1 subtype virus (McLain et al.,   1988 ). In fact, this is in line with the almost universal reassortment of full-length RNAs which takes place between influenza A strains, for which a requirement for mutual replication and encapsidation is mandatory. Nonetheless, this interaction is not universal as DI WSN did not protect mice against PR8 (McLain et al., 1992; unpublished data) .
DI EQV, but not inactivated DI EQV, was protective when given some days before infection further suggesting that protection was mediated by the DI genome rather than some other non-specific mechanism. Mice could be protected for up to 5 days, presumably due to the stability of the DI genome. This was also a property of DI WSN (L, McLain & N. J. Dimmock, unpublished data). Long-lived DI RNA with a half-life of 25 days has been seen in vitro when MDCK cells were inoculated with non-infectious DI WSN (Cane et al., 1987) , and long-lived virion RNA segment 4, encoding the HA, was found in cells inoculated with non-infectious u.v.-irradiated virus (Cane & Dimmock, 1990) . However, DI EQV afforded no protection when given after infection, as has been found with other DI viruses (Semliki Forest virus: Dimmock & Kennedy, 1978 ; WSN:
The ratio of WSN:DI EQV necessary for protection has been determined here for the first time. A chequerboard titration (Table 4) shows that protection depended upon the ratio of physical DI virus particles:standard virus particles rather than the absolute number of DI particles per mouse, so that a ratio of approximately 2 x 105 DI : standard virus particles was required for 25 % protection in the mortality system and a ratio of about 2x 104 for 38% protection in the morbidity system. However, in absolute terms 100-fold fewer DI particles were required to protect against the morbidity-causing dose of WSN compared with the higher, mortalitycausing dose. Although a large excess (about 2 x 104-fold) of DI over infectious virus particles was required for protection, a dose of only 1.2 ng DI virus/mouse gave significant benefit (Fig. 3 d) . Interestingly this is the first report of DI virus-mediated protection in a morbidity system, all other investigations having used a lethal dose of infectious virus (with vesicular stomatitis, Semliki Forest and influenza viruses: Dimmock, 1991) .
The conclusion that the ratio of DI:infectious virus controls protection agrees with the earlier but less complete studies using Semliki Forest virus (Dimmock & Kennedy, 1978; Barrett & Dimmock, 1984a) . It is not known how to interpret the fact that there is effective protection against low infectious inocula with proportionally low amounts of DI virus, since this means that there, is a diminishing chance of an infectious particle and a DI virus particle entering the same cell, and yet there is unanimous agreement that effective Table 2 . :~ Data shown in Fig. 3 . § Percentage protection against death (high dose WSN) or disease (low dose WSN).
II Ratio of physical particles ofDI EQV:WSN is based on an estimate of 107 particles/HAU and 10 particles/p.f.u. (Donald & Isaacs, 1954; Nakajima & Sugiura, 1977) . ¶ Corrected for mice given WSN alone surviving infection. ** Corrected for mice given WSN (morb.) alone, which did not become ill. NI), Not determined.
interference & vitro requires the majority of cells to contain at least one DI virus genome. One explanation is that influenza virus initially infects relatively few cells in the respiratory tract and that there are sufficient DI particles to protect those cells. Around 4× 10"DI particles (Table 4) are required for protection from morbidity which, applying the Poisson distribution, means that only 2.5 × 106 cells in the respiratory tract of the mouse need to acquire a DI genome. The nature of the protection mediated by DI EQV against challenge by WSN differed substantially from protection in exactly the same system mediated by DI WSN . While both DI EQV and DI WSN were equally effective at preventing death in terms of the amount of DI virus inoculated/mouse, a body of evidence suggests that DI EQV protected mice by inhibiting virus multiplication in the lung, and that this in turn resulted in reduction of the characteristic lung immunopathology and consolidation, and of almost complete abrogation of morbidity. In contrast, DI WSN has no effect on virus multiplication and, although consolidation is reduced relative to lethally infected mice, all mice suffer substantial clinical disease before recovering Morgan et al., 1993) . It was postulated that immunopathogenesis during infection with WSN arose from the viral suppression of T cell functions. As lymphocytes are only abortively infected by influenza A viruses, suppression presumably resulted from limited expression of viral gene products. This inhibited the production of putative cellular signals which prevent further accumulation of T cells in the lung. Such uncontrolled accumulation is the cause of consolidation and the ultimate cause of death. Further, it was postulated that DI WSN also entered T cells and interfered in the normal way with infectious virus gene expression, and prevented the upset of T cell behaviour. Thus it appears that interference mediated by DI WSN in the mouse is cell-specific and prevents infectious virus gene expression in T (and other) cells, but not in the cells in the lung permissive for virus multiplication . DI EQV, on the other hand, inhibited virus multiplication, thus decreasing the antigen available for stimulating T cells and reducing immune-mediated pathology. We have not investigated whether nor not DI EQV is interfering in immune cells. The difference between DI WSN and DI EQV probably represents sequence differences between DI RNAs rather than any generic difference between DI particles of WSN and EQV. Such cell specificity is well-documented in vitro and relates both to generation, propagation and to the extent of interference of DI viruses in cells which support the multiplication of infectious virus (see review by Dimmock, 1991) . Differences between the modes of action of DI WSN and DI EQV presumably reside in their DI RNAs. We have isolated five putative DI RNAs from the lungs of mice inoculated with DI WSN+ 10 LD~o WSN, which are centrally deleted versions of the PB 1, PB2, PA and M virion RNAs (unpublished data). Which of these is responsible for the observed phenotype of DI WSN remains to be determined, as does the DI RNA content of DI EQV.
Against a background of poor efficacy of current vaccines against H3N8 equine influenza strains in horses Mumford et al., 1983 Mumford et al., , 1988 , this study suggests that DI EQV may have potential as an alternative prophylactic agent. Nanogram amounts are active and protection can be mediated by a single intranasal dose (Table 2 ). The protection persists for up to 5 days and extends to heterologous subtypes of type A influenza. In addition, administration of DI EQV+infectious virus gives solid resistance to a later lethal dose of challenge virus, suggesting a new format of live vaccine which uses DI virus in trans to attenuate the virulence of the co-inoculated standard virus (unpublished data). Testing DI EQV in horses against equine influenza is the next step.
